JAZZ Earnings Prediction
The chart below shows how JAZZ performed 10 days before and after its earnings report, based on data from the past quarters. Typically, JAZZ sees a -1.25% change in stock price 10 days leading up to the earnings, and a -1.29% change 10 days following the report. On the earnings day itself, the stock moves by -0.64%. This data can give you a slight idea of what to expect for the next quarter's release.
JAZZ Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
1.05B
8.52%
3.04%
Gross Margin
74.50%
1.28%
0.54%
Operating Margin
24.67%
39.14%
26.64%
Net Margin
20.38%
34.97%
23.82%
EPS
3.42
59.81%
37.35%
No Data Available
JAZZ Earnings Analysis
Jazz Pharmaceuticals, Inc. Corporation (JAZZ.O) Earnings Conference Call
Positive
Third Quarter Revenue Increase: Total revenue for the third quarter of 2024 was more than $1.05 billion, representing a 9% increase compared to the third quarter of 2023.
Xywav Sales Growth: Xywav net product sales grew 17% year-over-year to approximately $388 million, and we expect Xywav to continue to be the oxybate of choice in both narcolepsy and IH.
Quarterly Net Income Increase: Our adjusted net income of $417 million for the quarter represents a 23% increase compared to the third quarter of last year.
Cash Flow Generation: We generated approximately $400 million in cash from operations in the third quarter and roughly $1 billion through the first three quarters of the year.
Product Growth Momentum: We continue to see strong growth among a number of our products that are currently on the market.
Negative
Neuroscience Sales Surge: The durability of our neuroscience therapeutic area was underscored by both Xywav and Epidiolex posting record quarterly sales and year-over-year double digit growth.
Oncology Revenue Growth: Our oncology business reported 9% revenue growth year-over-year, including a strong quarter for Zepzelca.
Oxybate Treatment Leadership: In our neuroscience therapeutic area, Xywav remains the oxybate of choice as the number one branded treatment for narcolepsy and the only approved therapy for idiopathic hypersomnia or IH.
Revenue Impact from Protocols: We expect the new protocols will have a temporary negative impact on third quarter and fourth quarter Ryaz revenue, after which we expect demand to normalize by early next year.
Pediatric Utilization and Expansion: We are seeing high utilization in the pediatric population and are continuing to roll out programs to drive adoption in the adolescent and young adult market.
JAZZ FAQs
How does JAZZ typically perform around its earnings report dates?
Is Jazz Pharmaceuticals plc (JAZZ) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
JAZZ Earning Call Sentiment
Jazz Pharmaceuticals plc (JAZZ) Q3 2024 Earnings Call Transcript
JAZZ.O
1.4%Positive
The earnings call highlights strong financial performance with a 9% revenue increase and a 23% rise in adjusted net income. The company has significant cash reserves and flexibility for investments. Despite some risks in market adoption and clinical trials, management's optimistic guidance and strategic pipeline prioritization are promising. The increased share repurchase program and strong product growth further support a positive outlook. However, the lowered oncology revenue guidance due to temporary factors and management's evasiveness on certain issues temper the optimism slightly, leading to a positive but not strong positive sentiment.
